As TLCD1 has been previously implicated in the development of non-alcoholic steatohepatitis and liver cancer (5, 26), it may be of interest to develop TLCD1 inhibitors based on the structure of thiamine and explore their therapeutic potential. The gene discussed is TLCD1; the disease is metabolic dysfunction-associated steatohepatitis.